ArticleBMC endocrine disorders2025
Apparent diffusion coefficient: a predictor of the efficacy of glucocorticoid therapy in active moderate-severe thyroid eye disease: a retrospective cohort study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Teprotumumab treatment in an HIV-infected patient with refractory thyroid eye disease: clinical and quantitative MRI evidence.Frontiers in immunology · 2026Article
- Teprotumumab N01 for thyroid eye disease in China: clinical outcomes and quantitative MRI correlations.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo assess the association between the apparent diffusion coefficient (ADC) of extraocular muscles (EOMs) and the efficacy of glucocorticoid (GC) therapy in patients with active and moderate-severe thyroid eye disease (TED).
methodEighteen active and moderate-to-severe bilateral TED patients (responsive group, n = 8 patients (16 eyes); unresponsive group, n = 10 patients (20 eyes)) who underwent orbital long variable echo‑trains (Resolve)-diffusion tensor imaging (DTI) before GC therapy were retrospectively enrolled. The ADC values of each EOM were collected. The correlation between the ADC of EOMs and the efficacy of GC therapy was analyzed.
resultsAge was significantly younger in the responsive group compared with the unresponsive group (52.13 ± 5.18 years vs. 58.80 ± 9.33 years, P value = 0.02).There were no statistical differences in sex, smoking, TED duration, visual acuity, intraocular pressure, exophthalmos, clinical activity score, the levels of free triiodothyronine, free tetraiodothyronine thyroid-stimulating hormone, and thyroid-stimulating hormone receptor antibody between the responsive group and the unresponsive group. Apparent diffusion coefficient in the responsive group were significantly lower than that in the unresponsive group in superior rectus muscle (1351.17 ± 232.12 vs. 1624.36 ± 193.70, P value = 0.001) and medial rectus muscle (1420.69 ± 192.05 vs. 1697.00 ± 199.89, P value = 0.001). After age, sex and CAS adjustment, ADC of the superior rectus muscle and medial rectus muscle were independent predictors of the response to GC treatment by binary logistic regression analysis. The cut-off value of ADC was 1582.00 × 10
conclusionsApparent diffusion coefficient values of EOMs from resolve DTI can be used as an indicator to predict the efficacy of GC therapy. Moderate-to-severe active TED patients with low ADC values at baseline in superior rectus muscle or medial rectus muscle may respond well to GC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.